Last reviewed · How we verify
Autologous Muscle Progenitor Cells
Autologous Muscle Progenitor Cells is a Biologic drug developed by Wake Forest University. It is currently in Phase 1 development. Also known as: MPCs.
At a glance
| Generic name | Autologous Muscle Progenitor Cells |
|---|---|
| Also known as | MPCs |
| Sponsor | Wake Forest University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Infection with unknown ANC
- Pain at amputation site
- Fever with unknown origin
- Colitis
- Wound developed on non-index foot
- Nausea
- Iliac crest pain, post bone marrow aspiration
- Hyponatremia
- Hypokalemia
- Oral Candidiasis
- Chronic anemia, worsening
- Encephalopathy
Key clinical trials
- Muscle Stem Cell Quality in Atrophy
- Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia (PHASE1, PHASE2)
- HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.
- Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (PHASE2)
- Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD (PHASE1)
- Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia (PHASE1)
- Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA) (PHASE1)
- Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Muscle Progenitor Cells CI brief — competitive landscape report
- Autologous Muscle Progenitor Cells updates RSS · CI watch RSS
- Wake Forest University portfolio CI
Frequently asked questions about Autologous Muscle Progenitor Cells
What is Autologous Muscle Progenitor Cells?
Autologous Muscle Progenitor Cells is a Biologic drug developed by Wake Forest University.
Who makes Autologous Muscle Progenitor Cells?
Autologous Muscle Progenitor Cells is developed by Wake Forest University (see full Wake Forest University pipeline at /company/wake-forest-university).
Is Autologous Muscle Progenitor Cells also known as anything else?
Autologous Muscle Progenitor Cells is also known as MPCs.
What development phase is Autologous Muscle Progenitor Cells in?
Autologous Muscle Progenitor Cells is in Phase 1.
What are the side effects of Autologous Muscle Progenitor Cells?
Common side effects of Autologous Muscle Progenitor Cells include Infection with unknown ANC, Pain at amputation site, Fever with unknown origin, Colitis, Wound developed on non-index foot, Nausea.
Related
- Manufacturer: Wake Forest University — full pipeline
- Also known as: MPCs
- Compare: Autologous Muscle Progenitor Cells vs similar drugs
- Pricing: Autologous Muscle Progenitor Cells cost, discount & access